Momentum Indicator for BIO turns negative, indicating new downward trend BIO saw its Momentum Indicator move below the 0 level on October 27, 2022. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 58 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 71%. Technical Analysis (Indicators) Bearish Trend Analysis The Moving Average Convergence Divergence Histogram (MACD) for BIO turned negative on October 28, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at . Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are . The Aroon Indicator for BIO entered a downward trend on October 21, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. Bullish Trend Analysis The RSI Indicator entered the oversold zone -- be on the watch for BIO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options. The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future. Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are . BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. Fundamental Analysis (Ratings) The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season. The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents. The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average. The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents. The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock. The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.179) is normal, around the industry mean (13.714). P/E Ratio (3.643) is within average values for comparable stocks, (143.802). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (6.429). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (3.709) is also within normal values, averaging (65.718). BIO is expected to report earnings to rise 30.00% to $3.38 per share on February 09 The last earnings report on October 27 showed earnings per share of $2.60, missing the estimate of $2.78. With 535.15K shares outstanding, the current market capitalization sits at 10.53B. Notable companies The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), Illumina (NASDAQ:ILMN), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH). Industry description Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets. Market Cap The average market capitalization across the Medical Specialties Industry is 5.62B. The market cap for tickers in the group ranges from 775 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is BIIO at 775. High and low price notable news The average weekly price growth across all stocks in the Medical Specialties Industry was 2%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -18%. AVCRF experienced the highest price growth at 60%, while PEYE experienced the biggest fall at -67%. Volume The average weekly volume growth across all stocks in the Medical Specialties Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -70% and the average quarterly volume growth was -11% Fundamental Analysis Ratings The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows Valuation Rating: 50 Seasonality Score: -8 (-100 ... +100) a manufacturer of life science research products and clinical diagnostics 1 DaySTOCK / NAMEPrice $Chg $Chg %DXPE28.100.87+3.20%DXP EnterprisesPNW68.301.83+2.75%Pinnacle West Capital CorpAMPL16.490.39+2.42%AmplitudeGSMG1.540.02+1.32%Glory Star New Media Group Holdings LimitedOP0.24N/A+0.67%OceanPal A.I.dvisor indicates that over the last year, BIO has been closely correlated with DHR. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then DHR could also see price increases. Ticker / NAMECorrelationTo BIO1D PriceChange %BIO100%-7.98%DHR - BIO81%Closely correlated+1.49%TMO - BIO80%Closely correlated+1.11%A - BIO75%Closely correlated+1.67%BRKR - BIO75%Closely correlated-0.65%PKI - BIO75%Closely correlated+0.47%More More